|
 
Last update: |
 |
|
|
13-Jan-2025
|
 |
|
|
Arch Hellen Med, 42(1), January-February 2025, 7-13 REVIEW The role of propranolol in cancer therapy Z. Malami,1,2 E. Papazoglou,2 K. Vogiatzidis,2 S. Zarogiannis1,2 |
Cancer, as one of the biggest challenges of healthcare systems globally, continues to have an increase in incidence and mortality. Genetic and environmental factors contribute to its development, and chronic stress is now recognized as a major risk factor. Under normal conditions, stress acts by activating the sympathetic nervous system to release the catecholamines adrenaline and noradrenaline, which bind to and activate beta-adrenergic receptors (β-ARs). However, the harmful effects of chronic stress have been associated with the development, progression and metastasis of several types of cancer, including breast, lung, prostate and ovarian cancers. Propranolol, a non-selective beta-blocker conventionally used in cardiovascular disorders, has gathered attention because of its anti-cancer properties. The therapeutic potential of propranolol has been studied in various types of cancer, in order to elucidate its diverse mechanisms of action, including modulating the immune response and enhancing conventional cancer therapies. Despite promising findings, the exact mechanisms remain poorly understood, necessitating further investigation into the potential of propranolol for more effective and comprehensive cancer treatment strategies.
Key words: Adrenergic inhibitors, β2 adrenergic receptors, Cancer, Chronic stress, Propranolol.
